Importantly, our preclinical findings also illustrate how pharmacologic manipulation of key cell cycle regulators (CDK1 and/or CDK2) can potentially limit the efficacy of WEE1 inhibitors in cancer patients. The gene discussed is CDK2; the disease is cancer.